Standalone Profit Declines 31% in Q3, Grows 13% in 9M; Consolidated Profit Soars 184% in Q3, Up 85% for 9M
Ahmedabad, January 30, 2025 – Hester Biosciences Limited has reported its unaudited standalone and consolidated financial results for the quarter (Q3 FY25) and nine-month period (9M FY25) ended December 31, 2024.
Seasonal changes, including early monsoon withdrawal.
Lower milk prices reducing farmer spending on cattle healthcare.
Ban on Nimesulide, leading to product recall; alternative in development.
Poultry Healthcare Division
Q3 revenue grew 12%, while 9M revenue expanded 22%.
Strong demand for vaccines (+20% in Q3, +27% in 9M), driven by Newcastle Disease and Marek’s Disease awareness.
New feed supplements and disinfectants launched in Q3.
Petcare Division
Rapid growth with 105% increase in Q3 and 38% in 9M.
Growth driven by:
Strong brand promotion and seasonal demand in antibiotics and grooming.
New pet food range launched, boosting market presence.
International Subsidiaries' Performance
Hester Nepal: 9M profit at ₹18.69 Mn vs. ₹20.21 Mn YoY; continues export growth.
Hester Africa: Net loss reduced to ₹5.65 Mn (vs. ₹134.87 Mn in FY24), supported by foreign exchange gains of ₹78.27 Mn due to Tanzanian Shilling appreciation.
Strategic Outlook
Launch of Avian Influenza Vaccine: Expected in 2025, strengthening the Poultry division.
Petcare Expansion: Ongoing investment to solidify market share.
International Growth: Targeting African market expansion through tenders and direct sales.
Management Commentary
Rajiv Gandhi, CEO & Managing Director, Hester Biosciences, stated: "Despite headwinds in Q3, our long-term growth trajectory remains intact, driven by our diversified portfolio. The upcoming Avian Influenza vaccine and Petcare segment expansion are expected to further strengthen our position. We remain committed to improving profitability while delivering innovative healthcare solutions for the animal industry."
Conclusion
While Q3 FY25 showed declines in standalone revenue and profitability, the 9M FY25 results remain positive, with consolidated net profit surging 85% YoY. The company remains optimistic about future growth, supported by new product launches, international expansion, and a focus on bottom-line improvement.